




The relative strengths and weaknesses of Kinnate Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kinnate Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 173% points. The greatest weakness of Kinnate Biopharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 336%, being 123% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	158,177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,995
Liabilities, Non-Current	2,283
Other Assets	13,156
Other Compr. Net Income	1,398
Other Expenses	2,168
Other Liabilities	0
Other Net Income	8,527
Other Revenues	0
Property and Equipment	2,272
Research and Development	90,767
Selling, General and Administrative Expense	28,241

Output Variable	Value in 1000 USD
Assets	173,605
Liabilities	14,278
Expenses	121,176
Revenues	0
Stockholders Equity	159,327
Net Income	-112,649
Comprehensive Net Income	-111,950
BaseVar	159,492
ECR before Limited Liability	251%
Economic Capital Ratio	336%